IL236233A - Azulophyrimidine-5- (6h) Compounds - Onion with Conjugated Thiophene or Puran - Google Patents

Azulophyrimidine-5- (6h) Compounds - Onion with Conjugated Thiophene or Puran

Info

Publication number
IL236233A
IL236233A IL236233A IL23623314A IL236233A IL 236233 A IL236233 A IL 236233A IL 236233 A IL236233 A IL 236233A IL 23623314 A IL23623314 A IL 23623314A IL 236233 A IL236233 A IL 236233A
Authority
IL
Israel
Prior art keywords
azolopyrimidine
furan
fused
compounds
substituted thiophene
Prior art date
Application number
IL236233A
Other languages
English (en)
Hebrew (he)
Other versions
IL236233A0 (en
Original Assignee
Dart Neuroscience (Cayman) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience (Cayman) Ltd filed Critical Dart Neuroscience (Cayman) Ltd
Publication of IL236233A0 publication Critical patent/IL236233A0/en
Publication of IL236233A publication Critical patent/IL236233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL236233A 2012-06-18 2014-12-14 Azulophyrimidine-5- (6h) Compounds - Onion with Conjugated Thiophene or Puran IL236233A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046403 WO2013192225A1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Publications (2)

Publication Number Publication Date
IL236233A0 IL236233A0 (en) 2015-02-01
IL236233A true IL236233A (en) 2016-10-31

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
IL236233A IL236233A (en) 2012-06-18 2014-12-14 Azulophyrimidine-5- (6h) Compounds - Onion with Conjugated Thiophene or Puran
IL236232A IL236232A (en) 2012-06-18 2014-12-14 Pyridine azulopyrimidine-5– (h6) compounds are prepared

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL236232A IL236232A (en) 2012-06-18 2014-12-14 Pyridine azulopyrimidine-5– (h6) compounds are prepared

Country Status (17)

Country Link
US (7) US9499562B2 (cg-RX-API-DMAC7.html)
EP (3) EP2861603B1 (cg-RX-API-DMAC7.html)
JP (2) JP6240180B2 (cg-RX-API-DMAC7.html)
KR (2) KR102087756B1 (cg-RX-API-DMAC7.html)
CN (2) CN104583213B (cg-RX-API-DMAC7.html)
AU (3) AU2013277298B2 (cg-RX-API-DMAC7.html)
BR (2) BR112014031730B1 (cg-RX-API-DMAC7.html)
CA (2) CA2877146C (cg-RX-API-DMAC7.html)
DK (2) DK2861603T3 (cg-RX-API-DMAC7.html)
ES (2) ES2715325T3 (cg-RX-API-DMAC7.html)
IL (2) IL236233A (cg-RX-API-DMAC7.html)
IN (2) IN2015DN00335A (cg-RX-API-DMAC7.html)
MX (2) MX359615B (cg-RX-API-DMAC7.html)
NZ (2) NZ703950A (cg-RX-API-DMAC7.html)
RU (2) RU2653054C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201408395WA (cg-RX-API-DMAC7.html)
WO (2) WO2013192225A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284792A1 (en) * 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training
MX359615B (es) 2012-06-18 2018-10-03 Dart Neuroscience Cayman Ltd Compuestos de azolpirimidina-5-(6h)-ona con tiofeno sustituido y furano fusionado.
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) * 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) * 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
MA46611B1 (fr) 2016-10-28 2020-08-31 H Lundbeck As Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
AU2017386417B2 (en) * 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CA3051976A1 (en) * 2017-02-23 2018-08-30 Boehringer Ingelheim International Gmbh New medical use of compound iii
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
WO2019104285A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
CN119330979A (zh) 2018-04-13 2025-01-21 癌症研究技术有限公司 作为bcl6抑制剂的化合物及其制备方法
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
JP2022545802A (ja) * 2019-08-22 2022-10-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
GB201914860D0 (en) * 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
WO2025024543A1 (en) * 2023-07-24 2025-01-30 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
AU2001284792A1 (en) 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
US9255099B2 (en) 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
US20100029697A1 (en) * 2007-03-28 2010-02-04 Debenham John S Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
BRPI0811623A2 (pt) 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
CA2695802A1 (en) * 2007-09-26 2009-04-02 Ge Healthcare Bioscience Bioprocess Corp. Three dimensional disposable bioreactor
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
GEP20146029B (en) * 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US9434730B2 (en) * 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
MX359615B (es) 2012-06-18 2018-10-03 Dart Neuroscience Cayman Ltd Compuestos de azolpirimidina-5-(6h)-ona con tiofeno sustituido y furano fusionado.

Also Published As

Publication number Publication date
IL236233A0 (en) 2015-02-01
MX2014015737A (es) 2015-09-16
JP6129960B2 (ja) 2017-05-17
AU2013277298B2 (en) 2017-09-07
CA2877149C (en) 2021-01-19
EP3489238A1 (en) 2019-05-29
RU2015100209A (ru) 2016-08-10
US10105367B2 (en) 2018-10-23
HK1208023A1 (en) 2016-02-19
NZ703949A (en) 2016-10-28
US9175010B2 (en) 2015-11-03
US9284335B2 (en) 2016-03-15
US9499562B2 (en) 2016-11-22
WO2013192229A8 (en) 2015-09-03
KR20150063028A (ko) 2015-06-08
US20160075719A1 (en) 2016-03-17
AU2013277294A1 (en) 2015-02-05
WO2013192225A1 (en) 2013-12-27
RU2659779C2 (ru) 2018-07-04
CN104583213B (zh) 2018-10-26
US20190046535A1 (en) 2019-02-14
HK1208024A1 (en) 2016-02-19
JP2015526394A (ja) 2015-09-10
US10092575B2 (en) 2018-10-09
BR112014031730B1 (pt) 2023-05-16
US9533996B2 (en) 2017-01-03
EP3489238B8 (en) 2022-02-16
BR112014031731A2 (pt) 2017-06-27
ES2715325T3 (es) 2019-06-03
AU2017272245B2 (en) 2019-08-29
CN104583217B (zh) 2017-11-17
RU2015100213A (ru) 2016-08-10
IN2015DN00335A (cg-RX-API-DMAC7.html) 2015-06-12
CA2877146C (en) 2020-10-20
SG10201703253XA (en) 2017-06-29
MX359615B (es) 2018-10-03
SG11201408397SA (en) 2015-01-29
JP6240180B2 (ja) 2017-11-29
EP2861605B1 (en) 2017-05-03
DK2861603T3 (en) 2019-03-04
US20150158885A1 (en) 2015-06-11
US20160031901A1 (en) 2016-02-04
AU2017272245A1 (en) 2018-01-04
IN2015DN00334A (cg-RX-API-DMAC7.html) 2015-06-12
MX357320B (es) 2018-07-04
US10376514B2 (en) 2019-08-13
CN104583213A (zh) 2015-04-29
EP2861603A4 (en) 2015-11-11
AU2013277294C1 (en) 2018-02-08
EP2861605A1 (en) 2015-04-22
EP3489238B1 (en) 2021-10-13
CA2877146A1 (en) 2013-12-27
AU2013277298A1 (en) 2015-02-05
CA2877149A1 (en) 2013-12-27
MX2014015740A (es) 2015-11-06
AU2013277294B2 (en) 2017-04-13
US20130338139A1 (en) 2013-12-19
IL236232A0 (en) 2015-02-01
WO2013192229A1 (en) 2013-12-27
NZ703950A (en) 2016-10-28
JP2015526395A (ja) 2015-09-10
US20170182052A1 (en) 2017-06-29
EP2861603A1 (en) 2015-04-22
CN104583217A (zh) 2015-04-29
RU2653054C2 (ru) 2018-05-07
SG11201408395WA (en) 2015-01-29
DK3489238T3 (da) 2022-01-10
IL236232A (en) 2016-10-31
BR112014031730A2 (pt) 2017-06-27
KR102087756B1 (ko) 2020-03-12
KR102191816B1 (ko) 2020-12-17
ES2904267T3 (es) 2022-04-04
EP2861603B1 (en) 2018-12-19
EP2861605A4 (en) 2016-01-13
BR112014031731B1 (pt) 2022-12-06
US20170209459A1 (en) 2017-07-27
KR20150063030A (ko) 2015-06-08

Similar Documents

Publication Publication Date Title
IL236233A (en) Azulophyrimidine-5- (6h) Compounds - Onion with Conjugated Thiophene or Puran
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
ZA201503794B (en) Imidazopyridine compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
PL2836495T3 (pl) Związki tetrahydropirolotiazynowe
GB201209096D0 (en) Compounds
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201220684D0 (en) New compounds
GB201215368D0 (en) New compounds
GB201215369D0 (en) New compounds
GB201215370D0 (en) New compounds
GB201219690D0 (en) New compounds l
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218774D0 (en) Compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed